This reasonably well-conducted review concluded that long term use of thiazolidinedione doubles the risk of fracture in women with type 2 diabetes but does not produce a significant increase in fracture risk among men with type 2 diabetes. This conclusion accurately reflects the evidence of the review and appears likely to be reliable.
Study selection
Randomised controlled trials (RCTs) and controlled observational studies which compared fracture risk in patients with type 2 diabetes or impaired glucose tolerance taking thiazolidinedione with those not on the treatment were eligible for inclusion. Included studies had to be of at least one year's duration. Acceptable comparators were placebo or oral therapy with an active comparator.
Included studies used rosiglitazone or pioglitazone. Most studies used concomitant medications, of which the most common was metformin. There was considerable variation in baseline fracture risk between the studies. Duration ranged from one to four years. See URL for Additional Data field for online appendices containing result tables.
Two reviewers independently assessed the studies for inclusion in the review.
Assessment of study quality
The RCTs were assessed for validity using the criteria of allocation concealment and blinding. Both RCTs and observational studies were assessed for the monitoring and recording of adverse events.
It appears that two reviewers independently assessed the quality of the included studies and that disagreements were resolved through consensus.
Data extraction
Numerical outcome data and participant characteristics were extracted together with information on dose and duration of thiazolidinedione therapy for RCTs and data sources and exposure verification for observational studies.
Two reviewers independently performed the data extraction, with disagreements resolved through consensus.
Methods of synthesis
Pooled odds ratios (OR) with 95% confidence intervals (CI) were calculated using a Mantel-Haenszel fixed-effect model meta-analysis. Numbers needed to harm (NNH) were calculated. Statistical heterogeneity between the studies was assessed using the I 2 statistic, with a value of 50% or higher considered to indicate substantial heterogeneity. A priori sensitivity analyses were used to investigate the impacts of trial duration and statistical models on effect sizes. The fail-safe number (to assess publication bias) was also calculated. The incidence of fractures was significantly higher in the thiazolidinedione groups compared to control groups (OR 1.45, 95% CI: 1.18, 1.79, p<0.001, 10 RCTs). Statistical heterogeneity was moderate (I 2 = 27%). The analysis was dominated by two large reasonable quality RCTs. Subgroup analysis of the RCTs which reported data separately for men and women, showed that women in thiazolidinedione groups had a significantly higher risk of fracture compared to controls (OR 2.23, 95% CI: 1.65, 3.01, p<0.001, n=4,400) but that there was no significant difference between the groups for men (OR 1.00, 95% CI: 0.73, 1.39, p=0.98, n=7,001). In neither case was there any statistically significant heterogeneity (I 2 = 0%). NNH varied from 55 (95% CI: 34, 103) in young newly diagnosed women to 21 (95% CI: 14, 39) in postmenopausal women. Results from the observational studies supported those of the RCTs.
